Clinical trial
CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in…
NCT03636269 · Cara Therapeutics, Inc., Industry · Completed
Key facts
| NCT number | NCT03636269 |
|---|---|
| Title | CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus |
| Official title | A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus, With a 52-Week Open Label Extension |
| Acronym | KALM-2 |
| Lead sponsor | Cara Therapeutics, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Uremic Pruritus |
| Intervention type | Drug |
| Interventions | CR845 0.5 mcg/kg, Placebo |
| Enrollment | 473 |
| Start date | Jul 17, 2018 |
| Primary completion | Mar 30, 2020 |
| Completion | Mar 30, 2020 |
| First posted | Aug 17, 2018 |
| Last update posted | Apr 26, 2022 |
| Countries | Australia, Canada, Czechia, Germany, Hungary, New Zealand, Poland, South Korea, Taiwan, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: